Dr. Clay Siegall is a renowned scientist. He is credited for making positive contributions in the industry, including propelling research in field of cancer therapy. He is the CEO of Seattle Genetics, a biotech firm that specializes in the development and commercialization of antibody-based therapies for cancer and other chronic diseases. Through his transformative leadership, the company has been able to register notable achievements, including the approval of their first antibody drug conjugate-ADC, Adcetris by FDA in 2011. Moreover, he has pushed for the commercialization of Adcetris by entering into multiple partnerships.
Speaking to Inspirery, the visionary leader said that was inspired to venture into genetics after seeing a family member suffer from cancer treatment. Driven by the desire to create alternative treatments that would cause less harm to patients, he advanced his studies in genetics before co-founding Seattle Genetics. The successful company makes money from the sale of their own drugs. In addition, substantial revenues are sourced from its production collaborations. The company also makes money from licenses arising from Seattle Genetics’ technologies.
About Clay Siegall
Dr. Clay Siegall holds a BS in zoology and a PhD in genetics from the renowned University of Maryland and George Washington University respectively. His visionary leadership at Seattle Genetics has seen the biotechnology firm rise to greater heights in the industry. Under his leadership, the company has set a track record of developing the most innovative therapies that are based on rigorous research. Apart from the development and commercialization of Adcetris, Seattle Genetics has embarked on a pipeline development of more than 20 drugs. In addition, the company has entered into partnerships with other drug manufacturers like Genentech and Bayer.
Before starting his journey with Seattle Genetics, Clay Siegall had rendered his services in various companies, including the Bristol-Myers Squibb Pharmaceutical Research Institute, National Institute of Health and the National Cancer institute. Presently, he serves on the boards of Alder BioPharmaceuticals, the Washington Roundtable, Ultragenyx Pharmaceutical and Mirna Therapeutics. In 2013, the University of Maryland recognized Dr. Clay as the Alumnus of the Year for Computer, Math and Natural Sciences. The celebrated scientist has authored over 70 publications and holds 15 patents.